Patient perspectives on physician conflict of interest in industry-sponsored clinical trials for multiple sclerosis therapeutics

Andrew J. Solomon, Eran Klein, John R. Corboy, James L. Bernat

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

BACKGROUND: Pharmaceutical industry financial support of physicians, physician practices, and academic departments involved in multicenter industry-sponsored clinical trials of novel therapeutic agents is a relatively new and infrequently acknowledged source of potential physician conflict of interest. Detailed disclosure of these relationships to study participants is not uniformly a part of informed consent and documentation practices. OBJECTIVE: To understand attitudes of patients with multiple sclerosis concerning disclosure of potential physician-industry conflicts of interest created by clinical trials and how such disclosures may influence study participation METHODS: An anonymous online instrument was developed. RESULTS: 597 people with multiple sclerosis participated in the study. The study found that detailed disclosure of conflicts of interest is important to potential participants in industry-sponsored clinical trials for multiple sclerosis therapies and that the presence of these conflicts of interest may influence patients' decisions to participate in these studies. CONCLUSIONS: Findings from this study support a call for uniform guidelines regarding disclosure of physician-industry relationships to prospective research participants for industry-sponsored clinical trials.

Original languageEnglish (US)
Title of host publicationGetting to Good
Subtitle of host publicationResearch Integrity in the Biomedical Sciences
PublisherSpringer International Publishing
Pages498-506
Number of pages9
ISBN (Electronic)9783319513584
ISBN (Print)9783319513577
DOIs
StatePublished - Jul 23 2018
Externally publishedYes

Fingerprint

Conflict of Interest
Disclosure
Multiple Sclerosis
Industry
Clinical Trials
Physicians
Therapeutics
Financial Support
Drug Industry
Informed Consent
Documentation
Guidelines
Research

Keywords

  • Clinical trials
  • Conflict of interest
  • Industry-sponsored clinical trials
  • Multiple sclerosis
  • Professional conduct and ethics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Solomon, A. J., Klein, E., Corboy, J. R., & Bernat, J. L. (2018). Patient perspectives on physician conflict of interest in industry-sponsored clinical trials for multiple sclerosis therapeutics. In Getting to Good: Research Integrity in the Biomedical Sciences (pp. 498-506). Springer International Publishing. https://doi.org/10.1177/1352458515569101

Patient perspectives on physician conflict of interest in industry-sponsored clinical trials for multiple sclerosis therapeutics. / Solomon, Andrew J.; Klein, Eran; Corboy, John R.; Bernat, James L.

Getting to Good: Research Integrity in the Biomedical Sciences. Springer International Publishing, 2018. p. 498-506.

Research output: Chapter in Book/Report/Conference proceedingChapter

Solomon, AJ, Klein, E, Corboy, JR & Bernat, JL 2018, Patient perspectives on physician conflict of interest in industry-sponsored clinical trials for multiple sclerosis therapeutics. in Getting to Good: Research Integrity in the Biomedical Sciences. Springer International Publishing, pp. 498-506. https://doi.org/10.1177/1352458515569101
Solomon AJ, Klein E, Corboy JR, Bernat JL. Patient perspectives on physician conflict of interest in industry-sponsored clinical trials for multiple sclerosis therapeutics. In Getting to Good: Research Integrity in the Biomedical Sciences. Springer International Publishing. 2018. p. 498-506 https://doi.org/10.1177/1352458515569101
Solomon, Andrew J. ; Klein, Eran ; Corboy, John R. ; Bernat, James L. / Patient perspectives on physician conflict of interest in industry-sponsored clinical trials for multiple sclerosis therapeutics. Getting to Good: Research Integrity in the Biomedical Sciences. Springer International Publishing, 2018. pp. 498-506
@inbook{06d851dcd90347268db1908167f2c8ec,
title = "Patient perspectives on physician conflict of interest in industry-sponsored clinical trials for multiple sclerosis therapeutics",
abstract = "BACKGROUND: Pharmaceutical industry financial support of physicians, physician practices, and academic departments involved in multicenter industry-sponsored clinical trials of novel therapeutic agents is a relatively new and infrequently acknowledged source of potential physician conflict of interest. Detailed disclosure of these relationships to study participants is not uniformly a part of informed consent and documentation practices. OBJECTIVE: To understand attitudes of patients with multiple sclerosis concerning disclosure of potential physician-industry conflicts of interest created by clinical trials and how such disclosures may influence study participation METHODS: An anonymous online instrument was developed. RESULTS: 597 people with multiple sclerosis participated in the study. The study found that detailed disclosure of conflicts of interest is important to potential participants in industry-sponsored clinical trials for multiple sclerosis therapies and that the presence of these conflicts of interest may influence patients' decisions to participate in these studies. CONCLUSIONS: Findings from this study support a call for uniform guidelines regarding disclosure of physician-industry relationships to prospective research participants for industry-sponsored clinical trials.",
keywords = "Clinical trials, Conflict of interest, Industry-sponsored clinical trials, Multiple sclerosis, Professional conduct and ethics",
author = "Solomon, {Andrew J.} and Eran Klein and Corboy, {John R.} and Bernat, {James L.}",
year = "2018",
month = "7",
day = "23",
doi = "10.1177/1352458515569101",
language = "English (US)",
isbn = "9783319513577",
pages = "498--506",
booktitle = "Getting to Good",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Patient perspectives on physician conflict of interest in industry-sponsored clinical trials for multiple sclerosis therapeutics

AU - Solomon, Andrew J.

AU - Klein, Eran

AU - Corboy, John R.

AU - Bernat, James L.

PY - 2018/7/23

Y1 - 2018/7/23

N2 - BACKGROUND: Pharmaceutical industry financial support of physicians, physician practices, and academic departments involved in multicenter industry-sponsored clinical trials of novel therapeutic agents is a relatively new and infrequently acknowledged source of potential physician conflict of interest. Detailed disclosure of these relationships to study participants is not uniformly a part of informed consent and documentation practices. OBJECTIVE: To understand attitudes of patients with multiple sclerosis concerning disclosure of potential physician-industry conflicts of interest created by clinical trials and how such disclosures may influence study participation METHODS: An anonymous online instrument was developed. RESULTS: 597 people with multiple sclerosis participated in the study. The study found that detailed disclosure of conflicts of interest is important to potential participants in industry-sponsored clinical trials for multiple sclerosis therapies and that the presence of these conflicts of interest may influence patients' decisions to participate in these studies. CONCLUSIONS: Findings from this study support a call for uniform guidelines regarding disclosure of physician-industry relationships to prospective research participants for industry-sponsored clinical trials.

AB - BACKGROUND: Pharmaceutical industry financial support of physicians, physician practices, and academic departments involved in multicenter industry-sponsored clinical trials of novel therapeutic agents is a relatively new and infrequently acknowledged source of potential physician conflict of interest. Detailed disclosure of these relationships to study participants is not uniformly a part of informed consent and documentation practices. OBJECTIVE: To understand attitudes of patients with multiple sclerosis concerning disclosure of potential physician-industry conflicts of interest created by clinical trials and how such disclosures may influence study participation METHODS: An anonymous online instrument was developed. RESULTS: 597 people with multiple sclerosis participated in the study. The study found that detailed disclosure of conflicts of interest is important to potential participants in industry-sponsored clinical trials for multiple sclerosis therapies and that the presence of these conflicts of interest may influence patients' decisions to participate in these studies. CONCLUSIONS: Findings from this study support a call for uniform guidelines regarding disclosure of physician-industry relationships to prospective research participants for industry-sponsored clinical trials.

KW - Clinical trials

KW - Conflict of interest

KW - Industry-sponsored clinical trials

KW - Multiple sclerosis

KW - Professional conduct and ethics

UR - http://www.scopus.com/inward/record.url?scp=85063364371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063364371&partnerID=8YFLogxK

U2 - 10.1177/1352458515569101

DO - 10.1177/1352458515569101

M3 - Chapter

SN - 9783319513577

SP - 498

EP - 506

BT - Getting to Good

PB - Springer International Publishing

ER -